LAZARI CAPITAL MANAGEMENT, INC.
Position in GILD — Gilead Sciences, Inc.
CIK 1986389
WOODLAND HILLS, CA
Position in GILD
as of Mar 31, 2026
· filed Apr 24, 2026
Position Value
$263,688
+$27,782 QoQ
Shares Held
1,892
-1.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026LAZARI CAPITAL MANAGEMENT, INC. holds $11,558,274 across 8 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
16,094 | $4,049,894 | |
| 2 | JNJ |
Johnson & Johnson
|
6,179 | $1,569,280 | |
| 3 | PFE |
Pfizer Inc
|
64,489 | $1,552,895 | |
| 4 | LLY |
ELI LILLY & Co
|
1,119 | $1,342,162 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
17,208 | $991,524 | |
| 6 | MRK |
Merck & Co., Inc.
|
5,710 | $733,735 | |
| 7 | AMGN |
Amgen Inc
|
1,870 | $677,164 | |
| 8 | GSK |
GSK plc
|
12,240 | $641,620 |
All Filings in GILD
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $263,688 | 1,892 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $235,906 | 1,922 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $202,464 | 1,824 | Shares | Sole | 2025-10-28 | |
| 2024-12-31 | $319,877 | 3,463 | Shares | Sole | 2025-01-24 | |
| 2024-09-30 | $932,971 | 11,128 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $1,577,686 | 22,995 | Shares | Sole | 2024-09-09 | |
| 2024-03-31 | $1,505,067 | 20,547 | Shares | Sole | 2024-06-24 | |
| 2023-12-31 | $1,663,135 | 20,530 | Shares | Sole | 2024-02-27 | |
| 2023-09-30 | $1,534,171 | 20,472 | Shares | Sole | 2023-11-07 | |
| 2023-06-30 | $1,582,170 | 20,529 | Shares | Sole | 2023-07-20 | |
| No filing history on record for this holder in this stock. | ||||||